Merck failed to excite investors with its financial guidance for 2007 and 2008, causing a temporary stock drop, but analysts were reluctant to condemn the drugmaker.
What we said In "Merck Is on the Mend" (Feb. 5), we recommended a second look at the pharma giant, which was recovering from the low it reached in 2004 amid the Vioxx debacle. We mentioned that Merck was winning approvals for a host of new drugs, including cervical-cancer vaccine Gardasil. We cited Bear Stearns analyst John Boris's year-end price target of $53.
Merck's cervical cancer vaccine Gardasil now faces direct competition from Glaxo's Cervarix, which was approved by European health authorities, said the vaccine's maker GlaxoSmithKline on Monday.
Men should be vaccinated against a sexually transmitted wart virus to protect them against a type of mouth and throat cancer, U.S. researchers said Monday.
TThe drug helps protect teenage girls from the virus that can cause cervical cancer, but a new study shows it does little to help women who already are already infected
The French government has agreed to subsidize a cervical cancer vaccine made by Merck for teenage girls and young women, according to Merck's marketing partner, French drugmaker Sanofi-Aventis.
GlaxoSmithKline announced the results of the biggest-ever study of a cancer vaccine Wednesday, in the hopes of bolstering the competitive strength of its Cervarix against Merck's Gardasil.
Merck failed to excite investors with its financial guidance for 2007 and 2008, causing a temporary stock drop, but analysts were reluctant to condemn the drugmaker.
What we said In "Merck Is on the Mend" (Feb. 5), we recommended a second look at the pharma giant, which was recovering from the low it reached in 2004 amid the Vioxx debacle. We mentioned that Merck was winning approvals for a host of new drugs, including cervical-cancer vaccine Gardasil. We cited Bear Stearns analyst John Boris's year-end price target of $53.
Merck's cervical cancer vaccine Gardasil now faces direct competition from Glaxo's Cervarix, which was approved by European health authorities, said the vaccine's maker GlaxoSmithKline on Monday.
Men should be vaccinated against a sexually transmitted wart virus to protect them against a type of mouth and throat cancer, U.S. researchers said Monday.
TThe drug helps protect teenage girls from the virus that can cause cervical cancer, but a new study shows it does little to help women who already are already infected
The French government has agreed to subsidize a cervical cancer vaccine made by Merck for teenage girls and young women, according to Merck's marketing partner, French drugmaker Sanofi-Aventis.
GlaxoSmithKline announced the results of the biggest-ever study of a cancer vaccine Wednesday, in the hopes of bolstering the competitive strength of its Cervarix against Merck's Gardasil.
The drugmakers Merck, Schering-Plough and Wyeth all reported strong first-quarter earnings - with Schering and Wyeth trouncing forecasts - but investor reaction was mixed.
GlaxoSmithKline said it submitted an application for its cervical cancer vaccine Cervarix to the Food and Drug Administration, bringing it one step closer to challenging Merck's now-dominant Gardasil.
The British drugmaker GlaxoSmithKline fired a shot over Merck's bow on Thursday, by launching a study comparing its own experimental vaccine for cervical cancer to Merck's Gardasil.
Big Pharma stocks trounced Big Biotech this year, as Merck and other drugmakers recovered from their woes, and Genentech slid after a couple of very good years.
On the site of a former amusement park in a small Pennsylvania town, technicians sheathed in plastic suits labor over stainless steel fermentation tanks that look like brewery vats.
Big Pharma is feeling the squeeze as name-brand drugs go off patent, which is why analysts are expecting a flat or modest second quarter for most of the biggest U.S. drug makers.
Vital protection against cervical cancer could soon be made available, not just from Merck but also from GlaxoSmithKline, providing life-saving potential for women while feeding a competitive atmosphere for the drug giants.
Merck has already angered Christian conservatives by pushing to make its yet-to-be approved cervical cancer vaccine, Gardasil, mandatory for girls as young as nine. But that could be the least of the company's worries regarding the projected $4 billion-a-year vaccine.
JUDGING BY THE HEADLINES, IT WOULD BE EASY TO THINK that Big Pharma is on the brink of collapse. In 2006 the industry is poised to lose more than $23 billion in sales to generic competitors, its wo...
Merck, the second-biggest American drug maker, said on Friday that its experimental cervical cancer vaccine Gardasil can also prevent external genital lesions in women, including vaginal and vulvar lesions.
Drugmakers are pouring billions of dollars into research and development in their quest for the next blockbusters, and analysts have a hard time gauging whether the heavy costs will pay off.
A cervical cancer vaccine that analysts are calling the biggest potential blockbuster in Merck & Co.'s pipeline passed the first phase in late-stage testing and will be filed with the Food and Drug Administration this year, the company said Thursday.
The page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.
Please try the following:
• If you typed the page address in the Address bar, make sure that it is spelled correctly.
• Open the edition.cnn.com home page and look for links to the information you want.
• Use the navigation bar above to find the link you are looking for.
• Click the Back button to try another link.
• Enter a term in the search form below to look for information on CNN sites or the Internet.
Video
